FDA Tries to End Dispute Between Brand-Name and Generic Drug Makers


From www.blogs.wsj.com –┬áDecember 4, 2014

The FDA is trying to bring brand name and generic drug makers together after vociferous complaints from generic drug makers that their brand-name counterparts have been exploiting an FDA risk-mitigation program, which is designed to boost patient safety, in order to thwart generic competition.

“The FDA has issued a so-called draft guidance that provides a road map for generic companies to obtain samples of medicines from brand-name rivals for product testing.”